B-cell precursor acute lymphoblastic leukemia (B-ALL) is the commonest childhood malignancy [1]. While most newly diagnosed patients can be cured, relapse outcomes remain poor, with resistant disease common [2]. Established relapse protocols, such as ALL R3, rely on highly intensive chemotherapy to induce remission but are associated with a significant risk of treatment-related mortality (TRM) [3, 4], limiting delivery of effective therapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Lamia
Contact Lamia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack